OIIA-LPD and genetic alteration
Project/Area Number |
18K16076
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 54010:Hematology and medical oncology-related
|
Research Institution | University of Tsukuba |
Principal Investigator |
|
Project Period (FY) |
2018-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2019: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 悪性リンパ腫 / 医原性リンパ増殖性疾患 / 次世代シーケンス / 遺伝子変異 / 自己免疫疾患 / メソトレキセート / シーケンス / 予後予測 |
Outline of Final Research Achievements |
We identified 64 cases of OIIA-LPD. Histological type in lymph node biopsy, autoimmune disease that triggered the initiation of oral administration of immunosuppressant, presence or absence of immunosuppressant, response after immunosuppressant discontinuation, presence or absence of chemotherapy, response to chemotherapy, and clinical information were extracted and analyzed. Similar to the previous report, about half of the histological types were DLBCL and about 1/3 were Hodgkin lymphoma. We were able to extract decent amount of genomic DNA from all of fresh frozen specimens and about half of the FFPE specimens for sequence analysis. A sequence library targeting the 412 gene associated with lymphoid tumor was prepared and sequenced with HiSeq 4000. In the future, we plan to analyze using sequence results and clinical information.
|
Academic Significance and Societal Importance of the Research Achievements |
自己免疫疾患に罹患した患者の治療薬としてメソトレキセートなどの免疫抑制剤は広く用いられている。そのような免疫抑制剤を内服している患者の一部にリンパ増殖性疾患という悪性リンパ腫に類似した病態を示すことがある。本研究はそのようなリンパ増殖性疾患(OIIA-LPD)を対象として、その組織型や免疫抑制剤中止への反応、抗がん剤を用いた化学療法の必要性などの情報を収集した。また診断の根拠となった臨床検体を材料として遺伝子変異を解析した。これらの結果を統合することでOIIA-LPDの臨床像や病態を明らかにすることを目的とした。
|
Report
(3 results)
Research Products
(18 results)
-
[Journal Article] Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status.2020
Author(s)
Shrestha R, Sakata-Yanagimoto M, Maie K, Oshima M, Ishihara M, Suehara Y, Fukumoto K,1 Nakajima-Takagi Y, Matsui H, Kato T, Muto H, Sakamoto T, Kusakabe M, Nannya Y, Makishima H, Ueno H, Saiki R, Ogawa S, Chiba K, Shiraishi Y, Miyano S, Mouly E, Bernard OA, Inaba T, Koseki H, Iwama A, Chiba S
-
Journal Title
Blood Adv.
Volume: 4(5)
Issue: 5
Pages: 845-854
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma.2020
Author(s)
Nguyen TB, Sakata-Yanagimoto M, Fujisawa M, Tanzima Nuhat S, Miyoshi H, Nannya Y, Hashimoto K, Fukumoto K, Bernard OA, Kiyoki Y, Ishitsuka K, Momose H, Sukegawa S, Shinagawa A, Suyama T, Sato Y, Nishikii H, Obara N, Kusakabe M, Yanagimoto S, Ogawa S, Ohshima K, Chiba S.
-
Journal Title
Cancer Res. 2020.
Volume: -
Issue: 9
Pages: 1875-1884
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis2018
Author(s)
Suma Sakurako、Sakata-Yanagimoto Mamiko、Nguyen Tran B.、Hattori Keiichiro、Sato Taiki、Noguchi Masayuki、Nannya Yasuhito、Ogawa Seishi、Watanabe Rei、Fujimoto Manabu、Nakamura Naoya、Kusakabe Manabu、Nishikii Hidekazu、Kato Takayasu、Chiba Shigeru
-
Journal Title
International Journal of Hematology
Volume: 108
Issue: 4
Pages: 447-451
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
[Journal Article] Droplet digital PCR assay and PNA-LNA clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma2018
Author(s)
Tanzima Nuhat S, Sakata-Yanagimoto M, Komori D, Hattori K, Suehara Y, Fukumoto K, Fujisawa M, Kusakabe M, Matsue K, Wakamatsu H, Shimadzu M, Chiba S
-
Journal Title
Cancer Sci
Volume: -
Issue: 5
Pages: 1682-1689
DOI
Related Report
Peer Reviewed / Open Access
-
-
-